<DOC>
	<DOCNO>NCT02526615</DOCNO>
	<brief_summary>The objective study compare effect rosiglitazone metformin insulin stimulate glucose uptake subject type 2 diabetes . Whole body , skeletal muscle , heart adipose tissue insulin stimulate glucose uptake measure euglycemic hyperinsulinemic clamp positron-emission tomography scan 26 week treatment 48 newly diagnose subject type 2 diabetes . Subjects randomize receive either rosiglitazone metformin placebo , accord simple randomization procedure double blinding .</brief_summary>
	<brief_title>Effects Rosiglitazone Metformin Metabolism Type 2 Diabetes</brief_title>
	<detailed_description>Insulin resistance pivotal underlie metabolic abnormality subject type 2 diabetes . Clinical experience prove metformin efficacious treatment patient type 2 diabetes . Rosiglitazone novel antidiabetic agent , show decrease fast plasma glucose concentration animal model clinical trial . There previous study compare effect rosiglitazone metformin insulin stimulate glucose uptake subject type 2 diabetic different organ . PET sensitive detecting change glucose uptake blood flow , method choice investigate effect medical intervention . Due sensitivity functional parameter moderate small number subject need study . This make feasible perform tightly control intervention study cost-effective way . The objective study compare effect rosiglitazone metformin insulin stimulate glucose uptake subject type 2 diabetes . PET measurement myocardium , skeletal muscle subcutaneous visceral fat perform baseline end treatment period . Furthermore , effect exercise skeletal muscle blood flow glucose uptake study . The study consist 48 newly diagnose subject type 2 diabetes . Subjects randomize receive either rosiglitazone metformin placebo , accord simple randomization procedure double blinding . The investigator also study ten age-matched non-diabetic control subject , undergo PET study procedure subject type 2 diabetes . A study effect antidiabetic oral medication newly diagnose subject type 2 diabetes great importance understanding difference mode action different antidiabetic drug . Such study would contribute elucidate advantage disadvantage certain drug potential additive effect combination therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 4075 year , BMI 2535 kg/m2 , WHO criteria type 2 diabetes fast plasma glucose &gt; =7.0 mmol/l least 2 separate occasion , Cpeptide &gt; 0.2 nmol/l plasma glucose &lt; 6.1 &gt; 10 mmol/l screen period cardiac heart failure diagnose coronary heart disease severe aortic , mitral tricuspidal valve disease blood pressure &gt; 160/ 100 mg Hg previous present hepatic ( GT &gt; 100 , alanine amino transferase &gt; 3 x upper limit reference range ) renal ( Screatinine &gt; 130 ) disease pregnancy lactation proliferative retinopathy microalbuminuria subject history lactate acidosis symptomatic polyneuropathy antidiabetic medication change antihypertensive medication betablockers medication metal object region image anemia Hb &lt; 100 mean &lt; 90 woman oral corticosteroid treatment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>metformin</keyword>
	<keyword>muscle</keyword>
</DOC>